ESPR
Esperion Therapeutics Inc.

9,335
Mkt Cap
$655.68M
Volume
7.37M
52W High
$4.18
52W Low
$0.6925
PE Ratio
-5.08
ESPR Fundamentals
Price
$3.04
Prev Close
$2.72
Open
$2.67
50D MA
$3.42
Beta
1.22
Avg. Volume
3.23M
EPS (Annual)
-$0.2764
P/B
-1.24
Rev/Employee
$1.09M
$858.25
Loading...
Loading...
News
all
press releases
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.2% - What's Next?
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.2% - Here's What Happened...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +14.07% and -10.76%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Royce & Associates LP Takes Position in Esperion Therapeutics, Inc. $ESPR
Royce & Associates LP purchased a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the third quarter, according to the company in its most recent filing with the...
MarketBeat·4d ago
News Placeholder
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.
Zacks·5d ago
News Placeholder
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1% - Should You Sell?
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% - Here's What Happened...
MarketBeat·6d ago
News Placeholder
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC
Needham & Company LLC raised their price target on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday...
MarketBeat·6d ago
News Placeholder
Esperion Therapeutics and Corstasis Therapeutics Announce Esperions Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray)
Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated...
Business Wire·6d ago
News Placeholder
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·13d ago
News Placeholder
Esperion Therapeutics (ESPR) to Release Earnings on Tuesday
Esperion Therapeutics (NASDAQ:ESPR) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 3. (View Earnings Report at...
MarketBeat·13d ago
<
1
2
...
>

Latest ESPR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.